Monali Manohar1, Diane Dunham1, Sheena Gupta2, Zheng Yan1, Wenming Zhang1, Samantha Minnicozzi3,4, Matthew Kirkey1, Bryan Bunning1, Roshni Roy Chowdhury5, Stephen J Galli1,5,6, Scott D Boyd1,6, Laurie Elizabeth Kost1, R Sharon Chinthrajah1, Manisha Desai7, Hans C Oettgen3,4, Holden T Maecker2,5, Wong Yu1, Rosemarie H DeKruyff1, Sandra Andorf1,8,9, Kari C Nadeau1. 1. Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA, USA. 2. Human Immune Monitoring Center, Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA, USA. 3. Division of Immunology, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA. 4. Department of Pediatrics, Harvard Medical School, Boston, MA, USA. 5. Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA. 6. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. 7. Department of Biomedical and Data Science, Stanford University, Stanford, CA, USA. 8. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 9. Divisions of Biomedical Informatics and Allergy & Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Abstract
BACKGROUND: Multifood oral immunotherapy (mOIT) with adjunctive anti-IgE (omalizumab, XOLAIR® ) treatment affords safe, effective, and rapid desensitization to multiple foods, although the specific immune mechanisms mediating this desensitization remain to be fully elucidated. METHODS: Participants in our phase 2 mOIT trial (NCT02643862) received omalizumab from baseline to week 16 and mOIT from week 8 to week 36. We compared the immune profile of PBMCs and plasma taken at baseline, week 8, and week 36 using high-dimensional mass cytometry, component-resolved diagnostics, the indirect basophil activation test, and Luminex. RESULTS: We found (i) decreased frequency of IL-4+ peanut-reactive CD4+ T cells and a marked downregulation of GPR15 expression and CXCR3 frequency among γδ and CD8+ T-cell subsets at week 8 during the initial, omalizumab-alone induction phase; (ii) significant upregulation of the skin-homing receptor CCR4 in peanut-reactive CD4+ T and Th2 effector memory (EM) cells and of cutaneous lymphocyte-associated antigen (CLA) in peanut-reactive CD8+ T and CD8+ EM cells; (iii) downregulation of CD86 expression among antigen-presenting cell subsets; and (iv) reduction in pro-inflammatory cytokines, notably IL-17, at week 36 post-OIT. We also observed significant attenuation of the Th2 phenotype post-OIT, defined by downregulation of IL-4 peanut-reactive T cells and OX40 in Th2EM cells, increased allergen component-specific IgG4/IgE ratio, and decreased allergen-driven activation of indirectly sensitized basophils. CONCLUSIONS: This exploratory study provides novel comprehensive insight into the immune underpinnings of desensitization through omalizumab-facilitated mOIT. Moreover, this study provides encouraging results to support the complex immune changes that can be induced by OIT.
BACKGROUND: Multifood oral immunotherapy (mOIT) with adjunctive anti-IgE (omalizumab, XOLAIR® ) treatment affords safe, effective, and rapid desensitization to multiple foods, although the specific immune mechanisms mediating this desensitization remain to be fully elucidated. METHODS: Participants in our phase 2 mOIT trial (NCT02643862) received omalizumab from baseline to week 16 and mOIT from week 8 to week 36. We compared the immune profile of PBMCs and plasma taken at baseline, week 8, and week 36 using high-dimensional mass cytometry, component-resolved diagnostics, the indirect basophil activation test, and Luminex. RESULTS: We found (i) decreased frequency of IL-4+ peanut-reactive CD4+ T cells and a marked downregulation of GPR15 expression and CXCR3 frequency among γδ and CD8+ T-cell subsets at week 8 during the initial, omalizumab-alone induction phase; (ii) significant upregulation of the skin-homing receptor CCR4 in peanut-reactive CD4+ T and Th2 effector memory (EM) cells and of cutaneous lymphocyte-associated antigen (CLA) in peanut-reactive CD8+ T and CD8+ EM cells; (iii) downregulation of CD86 expression among antigen-presenting cell subsets; and (iv) reduction in pro-inflammatory cytokines, notably IL-17, at week 36 post-OIT. We also observed significant attenuation of the Th2 phenotype post-OIT, defined by downregulation of IL-4 peanut-reactive T cells and OX40 in Th2EM cells, increased allergen component-specific IgG4/IgE ratio, and decreased allergen-driven activation of indirectly sensitized basophils. CONCLUSIONS: This exploratory study provides novel comprehensive insight into the immune underpinnings of desensitization through omalizumab-facilitated mOIT. Moreover, this study provides encouraging results to support the complex immune changes that can be induced by OIT.
Authors: David Chiang; Xintong Chen; Stacie M Jones; Robert A Wood; Scott H Sicherer; A Wesley Burks; Donald Y M Leung; Charuta Agashe; Alexander Grishin; Peter Dawson; Wendy F Davidson; Leah Newman; Robert Sebra; Miriam Merad; Hugh A Sampson; Bojan Losic; M Cecilia Berin Journal: J Allergy Clin Immunol Date: 2018-01-31 Impact factor: 10.793
Authors: Christina S K Yee; Sultan Albuhairi; Elizabeth Noh; Kristel El-Khoury; Shervin Rezaei; Azza Abdel-Gadir; Dale T Umetsu; Elizabeth Burke-Roberts; Jennifer LeBovidge; Lynda Schneider; Rima Rachid Journal: J Allergy Clin Immunol Pract Date: 2018-09-26
Authors: Wendy F Davidson; Donald Y M Leung; Lisa A Beck; Cecilia M Berin; Mark Boguniewicz; William W Busse; Talal A Chatila; Raif S Geha; James E Gern; Emma Guttman-Yassky; Alan D Irvine; Brian S Kim; Heidi H Kong; Gideon Lack; Kari C Nadeau; Julie Schwaninger; Angela Simpson; Eric L Simpson; Jonathan M Spergel; Alkis Togias; Ulrich Wahn; Robert A Wood; Judith A Woodfolk; Steven F Ziegler; Marshall Plaut Journal: J Allergy Clin Immunol Date: 2019-01-09 Impact factor: 10.793
Authors: A Abdel-Gadir; L Schneider; A Casini; L-M Charbonnier; S V Little; T Harrington; D T Umetsu; R Rachid; T A Chatila Journal: Clin Exp Allergy Date: 2018-05-29 Impact factor: 5.018
Authors: Thomas Suply; Sébastien Hannedouche; Nathalie Carte; Jianping Li; Bianka Grosshans; Michael Schaefer; Layla Raad; Valérie Beck; Solange Vidal; Agnès Hiou-Feige; Noémie Beluch; Samuel Barbieri; Johann Wirsching; Nadine Lageyre; Frank Hillger; Corinne Debon; Janet Dawson; Philip Smith; Vincent Lannoy; Michel Detheux; Francis Bitsch; Rocco Falchetto; Tewis Bouwmeester; Jeffrey Porter; Birgit Baumgarten; Keith Mansfield; José M Carballido; Klaus Seuwen; Frédéric Bassilana Journal: Sci Signal Date: 2017-09-12 Impact factor: 8.192
Authors: Cecilie Ammitzbøll; Marina R von Essen; Lars Börnsen; Eva Rosa Petersen; Oskar McWilliam; Rikke Ratzer; Jeppe Romme Christensen; Annette B Oturai; Helle B Søndergaard; Finn Sellebjerg Journal: J Autoimmun Date: 2018-09-21 Impact factor: 7.094
Authors: D Bedoret; A K Singh; V Shaw; E G Hoyte; R Hamilton; R H DeKruyff; L C Schneider; K C Nadeau; D T Umetsu Journal: Mucosal Immunol Date: 2012-02-08 Impact factor: 7.313
Authors: Andrew J MacGinnitie; Rima Rachid; Hana Gragg; Sara V Little; Paul Lakin; Antonella Cianferoni; Jennifer Heimall; Melanie Makhija; Rachel Robison; R Sharon Chinthrajah; John Lee; Jennifer Lebovidge; Tina Dominguez; Courtney Rooney; Megan Ott Lewis; Jennifer Koss; Elizabeth Burke-Roberts; Kimberly Chin; Tanya Logvinenko; Jacqueline A Pongracic; Dale T Umetsu; Jonathan Spergel; Kari C Nadeau; Lynda C Schneider Journal: J Allergy Clin Immunol Date: 2016-09-05 Impact factor: 10.793
Authors: Brinda Monian; Ang A Tu; Bert Ruiter; Duncan M Morgan; Patrick M Petrossian; Neal P Smith; Todd M Gierahn; Julia H Ginder; Wayne G Shreffler; J Christopher Love Journal: J Clin Invest Date: 2022-01-18 Impact factor: 14.808
Authors: Robert A Wood; R Sharon Chinthrajah; Alexander Eggel; Ivan Bottoli; Aurelie Gautier; Maximilian Woisetschlaeger; Paolo Tassinari; Pablo Altman Journal: World Allergy Organ J Date: 2022-09-13 Impact factor: 5.516
Authors: Xiaoying Zhou; Wong Yu; Diane M Dunham; Jackson P Schuetz; Catherine A Blish; Rosemarie H DeKruyff; Kari C Nadeau Journal: J Clin Invest Date: 2022-10-17 Impact factor: 19.456